Physician profile
Victor B Thomas
NPI 1730127572
$4,429.89
in general payments reported to CMS, 2019-2025
18 companies · $381 in 2025
The $381 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,354 · 2020: $111 · 2021: $456 · 2022: $1,031 · 2023: $459 · 2024: $638 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,624.49 | 2019-2025 | Clareon Panoptix Pro, Lensx, Clareon |
| Abbvie INC. | $755.89 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Amgen INC. | $240.79 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $202.78 | 2021-2024 | |
| Glaukos Corporation | $130.27 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $99.99 | 2022 | |
| Horizon Therapeutics Plc | $96.24 | 2022 | |
| Novartis Pharmaceuticals Corporation | $57.84 | 2019-2021 | |
| Ocular Therapeutix, INC. | $38.18 | 2023 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $30.57 | 2024 | Xdemvy |
| Dompe US, INC. | $25.20 | 2024 | Oxervate |
| Biotissue Holdings INC. | $24.00 | 2024 | |
| Kala Pharmaceuticals, INC. | $21.84 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $15.58 | 2025 | Ryzumvi, Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.58 | 2019 | |
| Allergan, INC. | $14.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.